1329651-11-7

1329651-11-7 structure
1329651-11-7 structure
  • Name: Mirodenafil-d7 dihydrochloride
  • Chemical Name: Mirodenafil-d7 dihydrochloride
  • CAS Number: 1329651-11-7
  • Molecular Formula: C26H32D7Cl2N5O5S
  • Molecular Weight: 611.63
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
  • Create Date: 2021-10-22 14:48:55
  • Modify Date: 2024-01-09 12:16:30
  • Mirodenafil-d7 (SK-3530-d7) dihydrochloride is the deuterium labeled Mirodenafil dihydrochloride. Mirodenafil dihydrochloride (SK3530 dihydrochloride) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction[1][2].

Name Mirodenafil-d7 dihydrochloride
Description Mirodenafil-d7 (SK-3530-d7) dihydrochloride is the deuterium labeled Mirodenafil dihydrochloride. Mirodenafil dihydrochloride (SK3530 dihydrochloride) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction[1][2].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med, 2008. 5(11): p. 2672-80.

[3]. Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther, 2009. 31(6): p. 1234-43.

[4]. Shin, K.H., et al., The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther, 2009. 31(12): p. 3009-20.

Molecular Formula C26H32D7Cl2N5O5S
Molecular Weight 611.63